1. Proteasome Inhibitors and Patients

3. RRMM Overview

4. Multiple Treatment Options Are Available for RRMM

5. Proteasome Inhibitors: Key Characteristics

6. ESMO Practice Guidelines: RRMM

7. Type of Relapse May Influence Treatment Decisions

8. Efficacy of Ixazomib in Patients With RRMM and High-Risk Cytogenetics: TOURMALINE-1 Trial

9. Choice of Proteasome Inhibitor at Relapse Depends on Multiple Factors

10. Patient Profile 1: Young and Fit

11. Prolonged Exposure to Proteasome Inhibitors Is Associated With Improved Outcomes

12. Duration of Exposure to IRd in the Phase 3 TOURMALINE-1 Trial

13. Weekly vs Twice Weekly Administration of Carfilzomib in RRMM: Phase 3 ARROW Trial

14. Bortezomib Maintenance Therapy Improves Depth of Response After ASCT

15. Ongoing Phase 3 Trials of Ixazomib as Maintenance Therapy

16. Patient Profile 2: Old and Frail

17. Safety Comparison of IRd vs Rd: Phase 3 TOURMALINE-1 Trial

18. Patient Profile 3: Comorbidities

19. Patient Profile 4: Disease-Related Factors

20. Selecting an Appropriate Treatment for the Patient With RRMM

21. Closing Remarks

22. Abbreviations

23. Abbreviations (cont)